Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markman, M.
Right arrow Articles by Alberts, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markman, M.
Right arrow Articles by Alberts, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 13 (July), 2003: 2460-2465
© 2003 American Society for Clinical Oncology

Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

Maurie Markman, P.Y. Liu, Sharon Wilczynski, Bradley Monk, Larry J. Copeland, Ronald D. Alvarez, Caroline Jiang, David Alberts

From the Cleveland Clinic Foundation, Cleveland; Ohio State University Health Center, Columbus, OH; Southwest Oncology Group Statistical Center, Seattle, WA; City of Hope National Medical Center, Duarte; University of California Irvine Medical Center, Orange, CA; University of Alabama Medical Center at Birmingham, Birmingham, AL; and University of Arizona Cancer Center, Tucson, AZ.

Address reprint requests to Maurie Markman, MD, The Cleveland Clinic Foundation (R35), 9500 Euclid Ave, Cleveland, OH 44195; email: markmam{at}ccf.org.

Purpose: To determine whether continuing paclitaxel for an extended time period in women with advanced ovarian cancer who had achieved a clinically defined complete response to a platinum/paclitaxel-based chemotherapy could prolong subsequent progression-free survival (PFS) and affect ultimate survival.

Patients and Methods: Patients were randomly assigned to either three or 12 cycles of single-agent paclitaxel administered every 28 days and were then followed up for progression-free and overall survival.

Results: As of September 6, 2001, 277 patients (262 assessable) had entered the trial, with a total of 54 PFS events having developed among 222 patients with follow-up data. With the exception of peripheral neuropathy, there were no major differences in toxicity between the regimens. The median PFS was 21 and 28 months in the three-cycle and 12-cycle paclitaxel arms, respectively. One-sided P values from an unadjusted log-rank test and an adjusted Cox model analysis (for stratification factors) were .0035 and .0023, respectively, both in favor of the 12-cycle arm. The Cox model-adjusted three-cycle versus the 12-cycle progression hazard ratio was estimated to be 2.31 (99% confidence interval, 1.08 to 4.94). With a protocol-specified early termination boundary of P = .005, these findings led the Southwest Oncology Group Data Safety Monitoring Committee to discontinue the trial. As of the date of study closure, there was no difference in overall survival between the treatment arms.

Conclusion: Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of PFS.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Pecorelli, G. Favalli, A. Gadducci, D. Katsaros, P. B. Panici, A. Carpi, G. Scambia, M. Ballardini, O. Nanni, and P. Conte
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
J. Clin. Oncol., October 1, 2009; 27(28): 4642 - 4648.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. P. McGuire
Maintenance Therapy for Ovarian Cancer: Of Helsinki and Hippocrates
J. Clin. Oncol., October 1, 2009; 27(28): 4633 - 4634.
[Full Text] [PDF]

Home page
 The OncologistHome page
C. W. Helm
The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
Oncologist, July 1, 2009; 14(7): 683 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Aebi, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv21 - iv23.
[Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, B. Freidlin, and M. Mooney
Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
J. Clin. Oncol., April 1, 2009; 27(10): 1712 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
Ann. Onc., February 1, 2009; 20(2): 294 - 297.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Berek, P. Taylor, W. McGuire, L. M. Smith, B. Schultes, and C. F. Nicodemus
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
J. Clin. Oncol., January 20, 2009; 27(3): 418 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al.
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Clin. Cancer Res., December 1, 2008; 14(23): 7781 - 7789.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. S. Kim, N.-H. Park, H. H. Chung, J. W. Kim, Y.-S. Song, and S.-B. Kang
Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?
Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 445 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Prat, M. Parera, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, I. Roxana, J. Baselga, and J. M. Del Campo
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
Ann. Onc., February 1, 2008; 19(2): 327 - 331.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
J. Clin. Oncol., September 10, 2007; 25(26): 4127 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. K. Tummala and W. P. McGuire
Ovarian Cancer, CA-125 Addiction, and Informed Confusion: Much Ado About Less
J. Clin. Oncol., August 20, 2007; 25(24): 3570 - 3571.
[Full Text] [PDF]

Home page
 JCOHome page
P.-Y. Liu, D. S. Alberts, B. J. Monk, M. Brady, J. Moon, and M. Markman
An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy
J. Clin. Oncol., August 20, 2007; 25(24): 3615 - 3620.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
Ann. Onc., April 1, 2007; 18(4): 716 - 721.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer
Oncologist, February 1, 2007; 12(2): 186 - 190.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al.
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer.
J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. P. McGuire
Is it time for some new approaches for treating advanced ovarian cancer?
J Natl Cancer Inst, August 2, 2006; 98(15): 1024 - 1026.
[Full Text] [PDF]

Home page
 NEJMHome page
C. N. Krasner, M. Roche, N. S. Horowitz, J. G. Supko, S. I. Lee, and E. Oliva
Case 11-2006 -- A 54-Year-Old Woman with a Mass in the Pelvis
N. Engl. J. Med., April 13, 2006; 354(15): 1615 - 1625.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. P. Rocconi, J. M. Straughn Jr., C. A. Leath III, L. C. Kilgore, W. K. Huh, M. N. Barnes III, E. E. Partridge, and R. D. Alvarez
Pegylated liposomal Doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Oncologist, April 1, 2006; 11(4): 336 - 341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Markman, P.Y. Liu, M. L. Rothenberg, B. J. Monk, M. Brady, and D. S. Alberts
Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer
J. Clin. Oncol., March 20, 2006; 24(9): 1454 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini and D. R. Spriggs
Consolidation for Ovarian Cancer in Remission
J. Clin. Oncol., February 1, 2006; 24(4): 537 - 539.
[Full Text] [PDF]

Home page
 JCOHome page
R. H. Verheijen, L. F. Massuger, B. B. Benigno, A. A. Epenetos, A. Lopes, J. T. Soper, J. Markowska, R. Vyzula, T. Jobling, G. Stamp, et al.
Phase III Trial of Intraperitoneal Therapy With Yttrium-90-Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission
J. Clin. Oncol., February 1, 2006; 24(4): 571 - 578.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
Additional Information
JAMA, November 2, 2005; 294(17): E1 - E3.
[Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
In Reply:
J. Clin. Oncol., April 20, 2005; 23(12): 2863 - 2864.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. M. Crawford and J. Peace
Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
Ann. Onc., January 1, 2005; 16(1): 47 - 50.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med., December 9, 2004; 351(24): 2519 - 2529.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Berek, P. T. Taylor, A. Gordon, M. J. Cunningham, N. Finkler, J. Orr Jr, S. Rivkin, B. C. Schultes, T. L. Whiteside, and C. F. Nicodemus
Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson
Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design
J. Clin. Oncol., August 1, 2004; 22(15): 3120 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al.
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. O. Schorge, R. D. Drake, H. Lee, S. J. Skates, R. Rajanbabu, D. S. Miller, J.-H. Kim, D. W. Cramer, R. S. Berkowitz, and S. C. Mok
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
Clin. Cancer Res., May 15, 2004; 10(10): 3474 - 3478.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
The Ethics of Early Stopping Rules: Who Is Protecting Whom?
J. Clin. Oncol., May 1, 2004; 22(9): 1542 - 1545.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sabbatini, C. Aghajanian, M. Leitao, E. Venkatraman, S. Anderson, J. Dupont, D. Dizon, C. O'Flaherty, J. Bloss, D. Chi, et al.
Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer: Results of a Phase I/II Trial
Clin. Cancer Res., May 1, 2004; 10(9): 2962 - 2967.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman
Ethical Conflict in Providing Informed Consent for Clinical Trials: A Problematic Example from the Gynecologic Cancer Research Community
Oncologist, February 1, 2004; 9(1): 3 - 7.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. F. Ozols
Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical Benefit
J. Clin. Oncol., July 1, 2003; 21(13): 2451 - 2453.
[Full Text] [PDF]

Home page
 JCOHome page
T. Thigpen
Maybe More Is Better
J. Clin. Oncol., July 1, 2003; 21(13): 2454 - 2456.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online